EP1303287A4 - In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung - Google Patents

In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung

Info

Publication number
EP1303287A4
EP1303287A4 EP01942207A EP01942207A EP1303287A4 EP 1303287 A4 EP1303287 A4 EP 1303287A4 EP 01942207 A EP01942207 A EP 01942207A EP 01942207 A EP01942207 A EP 01942207A EP 1303287 A4 EP1303287 A4 EP 1303287A4
Authority
EP
European Patent Office
Prior art keywords
ourexprimes
mhc
peptides
methods
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01942207A
Other languages
English (en)
French (fr)
Other versions
EP1303287A1 (de
Inventor
Forest White
Donald F Hunt
Jeffrey Shabanowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia UVA
Argonex Pharmaceuticals Inc
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Argonex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation, Argonex Pharmaceuticals Inc filed Critical University of Virginia UVA
Publication of EP1303287A1 publication Critical patent/EP1303287A1/de
Publication of EP1303287A4 publication Critical patent/EP1303287A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01942207A 2000-06-16 2001-06-15 In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung Withdrawn EP1303287A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21221300P 2000-06-16 2000-06-16
US21216500P 2000-06-16 2000-06-16
US212165P 2000-06-16
US212213P 2000-06-16
PCT/US2001/019207 WO2001097827A1 (en) 2000-06-16 2001-06-15 Mhc peptides over-expressed on prostate cancer cells and methods of use

Publications (2)

Publication Number Publication Date
EP1303287A1 EP1303287A1 (de) 2003-04-23
EP1303287A4 true EP1303287A4 (de) 2006-02-08

Family

ID=26906839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01942207A Withdrawn EP1303287A4 (de) 2000-06-16 2001-06-15 In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung

Country Status (3)

Country Link
EP (1) EP1303287A4 (de)
AU (1) AU2001275490A1 (de)
WO (1) WO2001097827A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
AUPR230500A0 (en) 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
EP3925968A3 (de) 2014-10-07 2022-03-02 Cytlimic Inc. Aus hsp70 gewonnenes peptid, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs unter verwendung davon, immunitätsinduzierer und verfahren zur herstellung von antigen-präsentierender zelle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US5846810A (en) * 1994-10-28 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Human 26S proteasome subunit components

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846810A (en) * 1994-10-28 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Human 26S proteasome subunit components
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORREALE P ET AL: "Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, 1998, pages 3186 - 3194, XP002975760, ISSN: 0022-1767 *
SCHMIDT WALTER ET AL: "Cell-free tumor antigen peptide-based cancer vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 7, 1997, pages 3262 - 3267, XP002168512, ISSN: 0027-8424 *
See also references of WO0197827A1 *
TJOA B A ET AL: "PROGRESS IN ACTIVE SPECIFIC IMMUNOTHERAPY OF PROSTATE CANCER", SEMINARS IN SURGICAL ONCOLOGY, vol. 18, no. 1, 2000, pages 80 - 87, XP000915524, ISSN: 8756-0437 *

Also Published As

Publication number Publication date
AU2001275490A1 (en) 2002-01-02
EP1303287A1 (de) 2003-04-23
WO2001097827A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
EP1018987A4 (de) Neo-knorpel und seine gebrauchsverfahren
DE60142955D1 (de) Batterieladeverfahren und batterieblock
DE69841509D1 (de) Lektrodenfomstück und elektrochemische elemente
PT1108039E (pt) Genes de alongases e suas utilizações
DE69923149D1 (de) Gelelektrolyt und Gelelektrolytbatterie
EP1311684A4 (de) Lactobacillus rhamnosus polynukleotide, polypeptide und methoden zu deren verwendung
AU7375100A (en) Water absorbent keratin and gel formed therefrom
DE69927649D1 (de) Batterielade- und Rückgabegerät
AU3952602A (en) Electrochemical coagulation assay and device
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
DE60118618D1 (de) Gelartiger polymerelektrolyt und zugehörige verwendung
DE50010609D1 (de) Sport-trainings-vorrichtung sowie sport-trainings-system
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
NO20004856L (no) Gelelektrolytt og gelelektrolyttcelle
EP1272111A4 (de) Omniaktivierbare tragbare chirugische instrumente
FR2805461B1 (fr) Nouveaux agents de gommage cutane et nouvelles compositions cosmetiques
EP1303287A4 (de) In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung
EP1590440A4 (de) Zellabtötende moleküle und vefahren zu deren verwendung
ITMI20001555A0 (it) Procedimento e dispositivo di trattamento elettrochimico
EP1161451A4 (de) Menschliches alpha-endokin und verfahren zu seiner verwendung
EP1218393A4 (de) Zellgerichtete zusammensetzungen und methoden zu deren verwendung
EP1263935A4 (de) Scytonemin und methoden seiner verwendung
EP1418194A4 (de) Modifiziertes polyalkylenimin und verfahren zu seiner verwendung
EP1308509A4 (de) Neuartiges, physiologisch aktives peptid und dessen anwendungen
EP1283727A4 (de) Zusammensetzungen und verfahren zum induzieren von aktivierung dentritischer zellen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030116

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 5/08 B

Ipc: 7C 12N 5/06 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 01N 63/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61K 38/04 B

Ipc: 7A 61K 38/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060715